EDAP TMS S.A. is engaged in developing and marketing the Ablatherm device, an advanced choice for intensity focused ultrasound (HIFU) treatment of localized prostate cancer. The Company operates two divisions: HIFU and urology devices and services (UDS) (including lithotripsy activities). Through these two divisions, the Company develops, produces and markets minimally invasive medical devices, mainly for urological diseases HIFU treatment is shown to be a minimally invasive treatment option for localized prostate cancer with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option. It is also used for patients who failed a radiotherapy treatment.